Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Actinium strikes deal with IBA for manufacture of leukemia drug therapy

IBA Molecular announced today that the company will spearhead development and manufacture of Actinium Pharmaceuticals’ radioimmunotherapy for acute and refractory myeloid leukemia patients who need bone marrow transplants.

Advanced Accelerator Applications keen on board consult from Kapil Dhingra

Kapil Dhingra, MBBS, previously the head of Roche Oncology, has been made a member of the board for radiopharmaceutical developers Advanced Accelerator Applications (AAA), the company announced last week.

Genetic variant protects brain from age-related memory decline

A particular genetic allele is now deemed a protector of memory in the aging brain as demonstrated by combined genetic testing and functional MRI, according to a study published May 1 in Biological Psychology.

Thumbnail

Patterns of a-synuclein are altered in patients with multiple dementias

Dementia patients with combinations of Alzheimer’s disease (AD), Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) show significantly different distribution of the protein alpha-synuclein than they would with one diagnosis, according to a presentation during last week’s annual meeting of the American Academy of Neurology (AAN).

Stem cell treatment for Alzheimer’s gets Americord support

An investigational therapy called Neurostem-AD developed by Medipost to treat the neurodegeneration caused by Alzheimer’s disease is currently in clinical trials and is now receiving financial backing from Americord, a cord blood, tissue and placenta bank, Americord officials announced today. 

Lumiphore scores SBIR grant for novel radiopharmaceuticals

Biopharmaceutical company Lumiphore, from Berkeley, Calif., has captured a Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation to develop novel macrocyclic chelating groups in an effort to create targeted radioisotope drug delivery systems, the company announced in April.

Thumbnail

AAN: Investigators gifted $260,000 for neurotoxin research

Two researchers received awards of $130,000 each for their work in developing treatments for Alzheimer’s and the movement disorder dystonia based on their research into neurotoxins, according to an announcement from the American Academy of Neurology (AAN) during the organization’s 66th annual meeting in Philadelphia.

Bristol Myers Squibb nabs iPierian in $175M buyout

Biopharmaceutical giant Bristol-Myers Squibb now holds the power on a pipeline of neurodegenerative disease therapies after buying San Francisco-based iPierian for $175 million.